Barreto SG, Windsor JA. Justifying vein resection with pancreatoduodenectomy. Lancet Oncol. 2016;17:e118–24.

Article  PubMed  Google Scholar 

Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2019;48:2053–108.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35:1641–9.

Article  PubMed  PubMed Central  Google Scholar 

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.

Article  PubMed  PubMed Central  CAS  Google Scholar 

O’Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015;60:547–60.

Article  PubMed  Google Scholar 

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen K-S, Reinshagen C, Van Schaik TA, Rossignoli F, Borges P, Mendonca NC, et al. Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity. Sci Transl Med. 2023;15:eabo4778.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377:2531–44.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for melanoma patients. Nature. 2017;547:217–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125:3401–12.

Article  PubMed  PubMed Central  Google Scholar 

Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165–82.

Article  PubMed  Google Scholar 

Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13: 964442.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24:S31-41.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023–39.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sterner RM, Hedin KE, Hayden RE, Nowakowski GS, Wyles SP, Greenberg-Worisek AJ, et al. A graduate-level interdisciplinary curriculum in CAR-T Cell therapy. Mayo Clin Proc Innov Qual Outcomes. 2020;4:203–10.

Article  PubMed  PubMed Central  Google Scholar 

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175–96.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21:78.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tsui CK, Barfield RM, Fischer CR, Morgens DW, Li A, Smith BAH, et al. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity. Nat Chem Biol. 2019;15:949–58.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ahmed M, Tezera LB, Elkington PT, Leslie AJ. The paradox of immune checkpoint inhibition re-activating tuberculosis. Eur Respir J. 2022;60:2102512.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–23.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315:1709–12.

Article  PubMed  CAS  Google Scholar 

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351:84–8.

Article  PubMed  CAS  Google Scholar 

Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA. 2012;109:E2579-2586.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu Z, Shi M, Ren Y, Xu H, Weng S, Ning W, et al. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Mol Cancer. 2023;22:35.

Article  PubMed  PubMed Central